Drug Profile
SMP 797
Alternative Names: SMP-797Latest Information Update: 30 Jan 2007
Price :
$50
*
At a glance
- Originator Dainippon Sumitomo Pharma
- Class Antihyperlipidaemics
- Mechanism of Action Sterol O-acyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hypercholesterolaemia
Most Recent Events
- 01 Oct 2005 Sumitomo Pharmaceuticals has merged with Dainippon Pharmaceutical to form Dainippon Sumitomo Pharma
- 13 May 2005 Phase-I clinical trials in Hypercholesterolaemia in Japan (unspecified route)
- 13 May 2005 Phase-II clinical trials in Hypercholesterolaemia in Europe (unspecified route)